Bronchogen Bronchoalveolar Lavage Price

Evaluating Bronchogen Pricing for Preclinical Bronchoalveolar Lavage Protocols

Bronchogen pricing for preclinical bronchoalveolar lavage (BAL) research typically ranges from $40 to $90 per vial depending on total peptide mass (e.g., 10 mg to 50 mg), analytical purity grade (HPLC > 98%), and institutional bulk volume tiering. Sourcing costs reflect stringent quality factors, including third-party mass spectrometry, endotoxin quantification, and domestic synthesis standards required for consistent pulmonary research data.

When evaluating the market for Bronchogen research peptides, laboratory investigators must look beyond nominal catalog costs. Substandard or unverified peptide samples often contain residual trifluoroacetic acid (TFA), truncated peptide sequences, or high endotoxin levels that alter inflammatory cell counts during lavage analysis, ultimately compromising experimental integrity.

For research facilities running multi-animal cohorts or high-throughput in vitro tissue cultures, institutional procurement through dedicated wholesale accounts provides tiered pricing schedules, guaranteeing batch uniformity across extensive study durations while reducing overall per-milligram expenditure.

What is Bronchogen? Molecular Profile and Bioregulatory Mechanism

Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-alpha-aspartyl-L-glutamyl-L-leucine (Ala-Asp-Glu-Leu). Categorized among short bioregulatory peptides, it was originally developed to model the signal transductive pathways of endogenous pulmonary tissue extracts. Preclinical research indicates that short peptide sequences interact directly with nuclear chromatin, binding specific promoter regions to influence DNA transcription.

In cell culture models of bronchial epithelium, Bronchogen has demonstrated the capacity to modulate cellular differentiation, alter histone modifications, and regulate expression patterns of structural proteins. Because short peptides bypass classical cell surface receptor binding, their mechanism relies on direct cellular uptake and nuclear localized regulatory interactions.

Understanding this molecular architecture is pivotal when establishing assay parameters. For investigators exploring the broader landscape of short synthetic signal molecules, reviewing our comprehensive research peptide catalog provides additional context regarding peptide length, charge, and sequence-specific nuclear binding behaviors.

The Role of Bronchoalveolar Lavage (BAL) in Preclinical Respiratory Models

Bronchoalveolar lavage (BAL) is a fundamental diagnostic and analytical technique utilized in preclinical respiratory models to evaluate cellular recruitment, cytokine production, and extracellular matrix remodeling within the lower respiratory tract. In rodent models of acute lung injury, chronic inflammation, or toxicant exposure, BAL fluid provides direct quantitative markers of mucosal barrier function.

During a typical BAL assay protocol, sterile buffer is instilled into the pulmonary lumen via a tracheal cannula and gently aspirated. The recovered BAL fluid is analyzed for total and differential leukocyte counts (e.g., alveolar macrophages, neutrophils, eosinophils), total protein content, and inflammatory mediator concentrations such as TNF-alpha, IL-1beta, IL-4, and IL-13.

When testing research peptides for pulmonary applications, researchers monitor changes in BAL markers to determine whether a compound attenuates neutrophil infiltration, preserves surfactant proteins, or modulates local cytokine expression. Accurate interpretation of BAL fluid parameters depends entirely on using high-purity, endotoxin-free test compounds.

Preclinical Literature: Bronchogen in Respiratory Epithelial Research

Preclinical investigations using rodent models of hypoxia and chronic airway inflammation suggest that Bronchogen administration alters pulmonary gene expression dynamics. In vitro assays using primary bronchial epithelial cell cultures indicate that the tetrapeptide upregulation of c-Fos and c-Jun transcription factors may correlate with enhanced epithelial cell proliferation and tissue repair mechanisms.

In animal studies involving toxicant-induced bronchitis, researchers evaluated BAL fluid parameters to track mucosal response over time. Experimental findings recorded reductions in neutrophilic inflammation and a normalization of alveolar macrophage activation states in cohorts exposed to short bioregulatory peptides compared to vehicle controls.

Furthermore, ex vivo explant models suggest that Bronchogen influences surfactant protein expression (SP-A and SP-B) in type II pneumocytes. While these findings highlight significant potential for understanding bronchial homeostasis, all observed mechanisms remain confined to in vitro and preclinical animal research models.

Cost Determinants in Research-Grade Peptide Procurement

The baseline price of research-grade Bronchogen is driven by several precise manufacturing and quality assurance variables. Solid-phase peptide synthesis (SPPS) of tetrapeptides requires rigorous purification steps to eliminate truncated sequence artifacts, unreacted coupling agents, and organic solvents.

Key cost drivers for analytical-grade Bronchogen include:

• Chromatographic Purification: Utilizing high-performance liquid chromatography (HPLC) to achieve > 98% sequence purity adds process cost but eliminates confounding peptide fragments.

• Endotoxin Elimination: Lowering lipopolysaccharide (LPS) levels below 0.01 EU/mg requires specialized desalting and ultrafiltration steps essential for BAL studies sensitive to endotoxin-induced inflammation.

• Mass Spectrometry Validation: Electrospray ionization mass spectrometry (ESI-MS) confirms exact molecular weight (460.44 g/mol), preventing false positives in biochemical assays.

• Lyophilization Quality: Advanced freeze-drying techniques ensure uniform moisture content, preventing rapid peptide degradation during laboratory storage.

Reconstitution, Handling, and Storage Standards for Laboratory BAL Assays

To ensure precise dosing in animal BAL protocols or in vitro cell assays, Bronchogen must be reconstituted according to strict laboratory practices. As a polar, hydrophilic tetrapeptide containing acidic amino acid residues (Asp, Glu), Bronchogen exhibits excellent solubility in aqueous buffers.

Reconstitution should be performed using sterile, endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4). Avoid forceful agitation; gentle swirling ensures complete dissolution without introducing mechanical shear or foaming. Stock solutions should be diluted under a laminar flow hood to maintain sterility.

For short-term experimental series, reconstituted Bronchogen solutions may be kept at 2°C to 8°C for up to 48 hours. For long-term preservation, lyophilized vials must be stored at -20°C or -80°C away from light and moisture. Aliquot reconstituted solutions to prevent freeze-thaw cycles, which degrade short peptide chains and cause concentration variances in lavage fluid calculations.

Comparative Analysis: Bronchogen vs. Related Bioregulatory Short Peptides

Evaluating short regulatory peptides requires comparing sequence length, tissue specificity, and experimental outcomes. While Bronchogen specifically targets bronchial and pulmonary epithelial pathways, other short synthetic peptides modulate distinct tissue systems through analogous nuclear interaction mechanisms.

For instance, Vilon (Lys-Glu) is a synthetic dipeptide extensively studied for its immunomodulatory effects and T-cell regulation in aging and inflammatory models. Similarly, Cortagen (Ala-Glu-Asp-Pro) targets central nervous system tissues and peripheral nerve repair pathways in preclinical nerve crush assays. In broader systemic bioregulation models, Epitalon (Ala-Glu-Asp-Gly) is investigated for telomerase activation and neuroendocrine synchronization. When designing preclinical protocols that cross pulmonary and systemic immune metrics, comparing these distinct sequences helps laboratories select the appropriate molecular target for their specific assay parameters.

Quality Assurance: COA Verification, HPLC, and Mass Spectrometry

To maintain publication-grade rigor, laboratories must verify that every peptide batch is accompanied by an independent Certificate of Analysis (COA). PX1 Research subjects every production lot to strict third-party verification at accredited ISO 17025 testing facilities.

Reverse-Phase HPLC (RP-HPLC) analysis establishes baseline chemical purity, ensuring that the target peak accounts for over 98% of total UV absorbance at 214 nm. Simultaneously, Mass Spectrometry (MS) confirms the correct monoisotopic mass and rules out residual heavy metals or unblocked side-chain protecting groups.

Given that BAL fluid analysis relies heavily on precise cellular and cytokine baseline counts, even minute contamination by bacterial endotoxins can induce severe artificial lung inflammation. PX1 Research performs quantitative Limulus Amebocyte Lysate (LAL) testing on all lot batches, providing verified endotoxin data that protects experimental validity.

Institutional Procurement, Wholesale Tiers, and Shipping Logistics

PX1 Research supports university research departments, private biotechnology firms, and contract research organizations (CROs) with streamlined procurement pipelines. Institutional clients benefit from custom volume quotes, batch reservation programs, and dedicated account support.

All research peptides are synthesized in state-of-the-art US-based laboratories operating under GMP-compliant protocols. This domestic supply chain avoids international customs delays and guarantees consistent material availability for multi-phase preclinical trials.

Orders placed before 3:00 PM PST Monday through Friday ship same-day from our dual dispatch facilities in California and Arizona. Lyophilized peptides are packaged in temperature-controlled, shock-resistant containers to ensure structural stability during transit. Learn more about establishing a institutional account on our wholesale page.